News

Dupixent, a fully-human monoclonal antibody, blocks the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. The regulator has provided breakthrough therapy device designation based on data from

Terns recently completed a Phase 1 clinical study of TERN-201, which demonstrated that single and multiple oral administrations of TERN-201 were well tolerated with no significant safety findings

The company has reported positive pre-clinical results and confirmed the efficacy of the vaccine on the live SARS CoV-2 virus. ACvac1 is a prophylactic COVID-19 vaccine designed to

Deliveries would be starting by the end of 2020, subject to clinical success and regulatory authorization. The companies will now enter into contract negotiations with the European Commission.

The FDA-approved strength for both COPD and asthma is fluticasone furoate / umeclidinium / vilanterol 100/62.5/25mcg. There is an additional strength for asthma alone which is fluticasone furoate

The fine has been imposed on the companies for pushing the sales of Lucentis to treat age-related macular degeneration (AMD) over Avastin, which is available at low cost

Cheplapharm is a specialty pharmaceutical company headquartered in Germany with a 25-year history of successfully acquiring, integrating and growing pharmaceutical products. Takeda will receive an upfront payment of

The agreement comes as Exelixis continues to build out its pipeline behind CABOMETYX (cabozantinib), its flagship product that is now a global oncology franchise. Under the terms of

AZD1222, which is currently in phase 3 trials, has been seen as one of the most promising vaccine candidates across the world that is likely to be approved